Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ITP
MCID: THR001
MIFTS: 53

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

About this section

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 71
Autoimmune Thrombocytopenia 25 58 29 54 71
Immune Thrombocytopenia 12 74 52 25 15
Immune Thrombocytopenic Purpura 25 71
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 25
Autoimmune Thrombocytopenic Purpura 25
Auto-Immune Thrombocytopenia 12
Werlhof Disease 25
Itp 25

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Blood diseases Immune diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:1587
NCIt 49 C3991
SNOMED-CT 67 2897005
ICD10 via Orphanet 33 D69.3
UMLS via Orphanet 72 C0242584
Orphanet 58 ORPHA71203
UMLS 71 C0242584 C0272286 C0398650
Sources

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

About this section
Genetics Home Reference : 25 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting. Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Small spots of bleeding under the skin are called purpura and larger spots are called ecchymoses. People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. In severe cases, individuals may have gastrointestinal bleeding or blood in the urine or stool, or heavy and prolonged menstrual bleeding (menorrhagia). In very rare instances, bleeding inside the skull (intracranial hemorrhage) can occur, which can be life-threatening. A greater reduction in platelet numbers is often associated with more frequent bleeding episodes and an increased risk of severe bleeding. While immune thrombocytopenia can be diagnosed at any age, there are two periods when the condition is most likely to develop: early childhood and late adulthood. In children, the reduction in platelets is often sudden, but platelet levels usually return to normal levels within weeks to months. Immune thrombocytopenia in children is often preceded by a minor infection, such as an upper respiratory infection, but the relationship between the infection and immune thrombocytopenia is not clear. In adults, the development of immune thrombocytopenia is usually gradual and the condition tends to persist throughout life.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as autoimmune thrombocytopenia, is related to purpura and thrombocytopenic purpura, autoimmune. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Immune thrombocytopenia purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a type of... more...

Sources

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia
Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1090)
# Related Disease Score Top Affiliating Genes
1 purpura 31.8 TNFSF13B THPO MPL ITGB3 ITGA2B IL10
2 thrombocytopenic purpura, autoimmune 31.7 THPO MPL ITGB3 ITGA2B ICOSLG FCGR2C
3 acquired thrombocytopenia 31.4 THPO MPL ITGB3
4 evans' syndrome 31.3 THPO MPL CD40LG
5 thrombocytosis 31.0 THPO PF4 MPL
6 thrombocytopenia 3 30.7 THPO MPL
7 crohn's disease 30.6 IL10 ICOSLG CD4 CCR6
8 acquired immunodeficiency syndrome 30.6 IL10 CD40LG CD4 CCR6
9 sarcoidosis 1 30.6 ICOSLG CD8A CD40LG CD4 CCR6
10 iga glomerulonephritis 30.6 PF4 ICOSLG CD40LG CCR6
11 igg4-related disease 30.6 TNFSF13B ICOSLG CD4 CCR6
12 infective endocarditis 30.6 PF4 ITGB3 FCGR2A
13 heparin-induced thrombocytopenia 30.6 PF4 FCGR2A CD40LG
14 thrombasthenia 30.6 ITGB3 ITGA2B ITGA2 GP9
15 qualitative platelet defect 30.5 PF4 ITGA2B
16 polyradiculoneuropathy 30.5 IL10 ICOSLG CD40LG
17 invasive aspergillosis 30.5 IL10 CD4 CCR6
18 immune deficiency disease 30.5 TNFSF13B IL10 ICOSLG CD40LG CD4 CCR6
19 polycythemia vera 30.5 THPO PF4 MPL ITGB3
20 marginal zone b-cell lymphoma 30.5 CD40LG CD19 CCR6
21 fetal and neonatal alloimmune thrombocytopenia 30.5 ITGB3 ITGA2B ITGA2
22 mycobacterium tuberculosis 1 30.5 IL10 ICOSLG CD8A CD4 CCR6
23 spondyloarthropathy 1 30.4 ICOSLG CD40LG CCR6
24 splenic sequestration 30.4 THPO MPL ITGA2B CD40LG CD4
25 anemia, autoimmune hemolytic 30.4 TNFSF13B ICOSLG CD8A CD40LG CD4 CD19
26 lymphadenitis 30.4 IL10 ICOSLG CD4 CCR6
27 monoclonal gammopathy of uncertain significance 30.4 ICOSLG CD40LG CD19 CCR6
28 miliary tuberculosis 30.4 CD8A CD40LG CD4
29 endocarditis 30.4 PF4 IL10 FCGR2A
30 von willebrand's disease 30.4 PF4 ITGB3 ITGA2 GP9
31 lupus erythematosus 30.3 IL10 FCGR2B FCGR2A CD40LG
32 acute disseminated encephalomyelitis 30.3 IL10 CD40LG CCR6
33 autoimmune gastritis 30.3 IL10 CD4 CCR6
34 thrombosis 30.3 PF4 MPL ITGB3 ITGA2B ITGA2 CD40LG
35 pfeiffer syndrome 30.3 CD8A CD40LG CD4 CD19 CCR6
36 essential thrombocythemia 30.3 THPO PF4 MPL ITGB3 ITGA2B CD40LG
37 sjogren syndrome 30.3 TNFSF13B IL10 IFNG-AS1 CD40LG
38 central nervous system vasculitis 30.3 CD8A CD40LG CD4 CCR6
39 chronic graft versus host disease 30.3 TNFSF13B IL10 CD4
40 severe cutaneous adverse reaction 30.3 CD8A CD40LG CD4
41 myelitis 30.2 IL10 ICOSLG CD40LG CCR6
42 bacterial sepsis 30.2 PF4 IL10 CCR6
43 portal hypertension 30.2 THPO CD40LG CD4
44 histoplasmosis 30.2 CD8A CD40LG CD4 CCR6
45 relapsing-remitting multiple sclerosis 30.2 TNFSF13B IL10 CD40LG CCR6
46 orchitis 30.2 IL10 CD8A CD40LG CD4
47 aplastic anemia 30.2 THPO MPL ITGB3 ITGA2B IL10 CD4
48 autoimmune disease 30.2 TNFSF13B IL10 ICOSLG FCGRT FCGR2B FCGR2A
49 mixed connective tissue disease 30.2 TNFSF13B IL10 CD40LG
50 cryoglobulinemia 30.2 TNFSF13B IL10 CD40LG

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization
Sources

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

About this section

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.09 CCR6 CD19 CD4 CD40LG CD8A FCGR2A
2 homeostasis/metabolism MP:0005376 9.77 CCR6 CD19 CD4 CD40LG FCGR2B FCGRT
3 immune system MP:0005387 9.47 CCR6 CD19 CD4 CD40LG CD8A FCGR2A
Sources

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
13
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
14
alemtuzumab Approved, Investigational Phase 4 216503-57-0
15
Clarithromycin Approved Phase 4 81103-11-9 84029
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
18
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
19
Enoxolone Investigational Phase 4 471-53-4 18526330
20 Antiparasitic Agents Phase 4
21 Antiprotozoal Agents Phase 4
22 Antimalarials Phase 4
23 Antimitotic Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Immunologic Factors Phase 4
26 Rho(D) Immune Globulin Phase 4
27 gamma-Globulins Phase 4
28 Immunoglobulins, Intravenous Phase 4
29 Immunosuppressive Agents Phase 4
30 Antifungal Agents Phase 4
31 Calcineurin Inhibitors Phase 4
32 Antilymphocyte Serum Phase 4
33
Tin Phase 4 7440-31-5
34 Tin Fluorides Phase 4
35 Fluorides Phase 4
36 Cariostatic Agents Phase 4
37 Pharmaceutical Solutions Phase 4
38 Antineoplastic Agents, Immunological Phase 4
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Vitamins Phase 4
42 Calcium, Dietary Phase 4
43 Micronutrients Phase 4
44 Trace Elements Phase 4
45 Vasoconstrictor Agents Phase 4
46 Nutrients Phase 4
47 Calciferol Phase 4
48
leucovorin Approved Phase 3 58-05-9 6006 143
49
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
50
Dapsone Approved, Investigational Phase 3 80-08-0 2955

Interventional clinical trials:

(show top 50) (show all 329)
# Name Status NCT ID Phase Drugs
1 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
4 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
5 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
6 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
7 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
8 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
9 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
10 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
11 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
12 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
13 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Recruiting NCT03784898 Phase 4
14 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
15 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
16 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
17 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
18 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
19 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
20 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
21 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
22 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
23 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
24 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
25 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Active, not recruiting NCT02760251 Phase 4 romiplostim
26 A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) Active, not recruiting NCT02255656 Phase 4 alemtuzumab GZ402673
27 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
28 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
29 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
30 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
31 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
32 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
33 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
34 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
35 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
36 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
37 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
38 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
39 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
40 Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
41 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
42 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
43 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
44 Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP). Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
45 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)
46 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
47 An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT01071954 Phase 3
48 Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3
49 Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3 Octagam 10%
50 A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura Completed NCT00511147 Phase 3

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate
Sources

Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29 FCGR2C
Sources

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

About this section

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

40
Bone, T Cells, Bone Marrow, B Cells, Thyroid, Liver, Lung
Sources

Publications for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 3309)
# Title Authors PMID Year
1
Investigation on glucocorticoid receptors within platelets from adult patients with immune thrombocytopenia. 61
31905108 2020
2
The effect of mycophenolate mofetil on platelet function. 61
31913146 2020
3
Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases. 61
31895126 2020
4
Cellular immune dysregulation in the pathogenesis of immune thrombocytopenia. 61
31977328 2020
5
Impact of CD40 gene polymorphisms on the risk of immune thrombocytopenic purpura. 61
32018016 2020
6
Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). 61
31554929 2020
7
A Case of Hashimoto's Thyroiditis with Multiple Drug Resistance and High Expression of Efflux Transporters. 61
31614366 2020
8
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. 61
32017466 2020
9
Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy. 61
32028499 2020
10
Taking Stock of Hemophilia, Immune Thrombocytopenia, and Bone Marrow Failure. 61
31900847 2020
11
FCGR polymorphisms and immune thrombocytopenia. 61
31520470 2020
12
Immune Thrombocytopenia in Children: Consensus and Controversies. 61
31927692 2020
13
Cutaneous thrombosis associated with eltrombopag treatment for immune thrombocytopenia. 61
31782189 2020
14
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. 61
31821591 2020
15
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. 61
31423574 2020
16
Management of immune thrombocytopenia in women: current standards and special considerations. 61
31903814 2020
17
Comment on: Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia. 61
32020778 2020
18
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. 61
31547724 2020
19
Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia. 61
31736241 2020
20
Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis. 61
31837028 2020
21
Genetic variants in toll-like receptor 4 are associated with lack of steroid-responsiveness in pediatric ITP patients. 61
31903617 2020
22
Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. 61
31021662 2020
23
Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: A single-center retrospective study. 61
31594025 2020
24
Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia. 61
31377437 2020
25
A novel mutation in the GP1BA gene in Bernard-Soulier syndrome. 61
31789661 2020
26
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. 61
31662412 2020
27
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. 61
31979293 2020
28
First line treatment of adult patients with primary immune thrombocytopenia: a real-world study. 61
30744465 2020
29
Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). 61
31557634 2020
30
LncRNA GAS5 inhibits Th17 differentiation and alleviates immune thrombocytopenia via promoting the ubiquitination of STAT3. 61
31978798 2020
31
Fatigue, executive function and psychological effects in children with immune thrombocytopenia: a cross-sectional study. 61
31978938 2020
32
Subdural haematoma in adults with Immune thrombocytopenia : A report on four cases. 61
31979927 2020
33
Comments on and assessments of 'Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis'. 61
31419842 2020
34
A Sticky Situation: Aortic Valve Thrombus in Patient with Anti-Phospholipid Antibody Syndrome and Immune Thrombocytopenia. 61
31987800 2020
35
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. 61
30785358 2020
36
Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia? 61
32004875 2020
37
Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP). 61
31900937 2020
38
Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. 61
31897887 2020
39
Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. 61
30885035 2020
40
A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. 61
31891657 2020
41
Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia. 61
31943136 2020
42
[Severe Thrombocitopenia Induced by Fenofibrate]. 61
31928604 2020
43
[Enteroviral infections in adults treated with rituximab: A new case of chronic meningitis and myofasciitis and literature review]. 61
31980187 2020
44
Treatment of Combined Autoimmune Neutropenia and Immune Thrombocytopenia with Methotrexate. 61
31256147 2020
45
Methylprednisolone-induced immune thrombocytopenia. 61
31598982 2020
46
Evaluation of thrombotic events in patients with immune thrombocytopenia. 61
31853702 2020
47
A comment on "a prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia" by Zhou et al. 61
31957064 2020
48
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. 61
31945156 2020
49
Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. 61
31805421 2020
50
[Diagnostic performance of κ/λ serum free light chain ratio (Freelite® assay) and IgGκ/IgGλ ratio (Hevylite® assay) as prognostic biomarkers of the evolution of immune thrombocytopenia into a chronic disease in adult patients]. 61
31722837 2020
Sources

Variations for Thrombocytopenia Due to Platelet Alloimmunization

About this section
Sources

Expression for Thrombocytopenia Due to Platelet Alloimmunization

About this section
Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.
Sources

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.96 TNFSF13B ITGB3 ITGA2B IL10 ICOSLG FCGR2C
2
ERK Signaling 63
Show member pathways
 13.77 TNFSF13B THPO PF4 ITGB3 ITGA2B ITGA2
3
TGF-Beta Pathway 63
Show member pathways
 13.5 TNFSF13B THPO MPL ITGB3 ITGA2B ITGA2
4
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.28 THPO PF4 MPL ITGB3 ITGA2B ITGA2
5
PAK Pathway 63
Show member pathways
 13.26 TNFSF13B THPO PF4 IL10 CD40LG CD4
6
Akt Signaling 63
Show member pathways
 13.25 TNFSF13B THPO PF4 ITGB3 ITGA2B ITGA2
7
Phospholipase-C Pathway 63
Show member pathways
 13.02 THPO ITGB3 ITGA2B ITGA2 FCGR2B FCGR2A
8
Allograft rejection 1 36
Show member pathways
 12.79 TNFSF13B IL10 ICOSLG CD8A CD40LG CD4
9
NF-kappaB Signaling 4
12.5 TNFSF13B MPL IL10 CD8A CD40LG CD19
10
Toxoplasmosis 36
Show member pathways
 12.22 IL10 FCGR2C FCGR2A CD40LG
11
Tuberculosis 36
12.19 IL10 FCGR2C FCGR2B FCGR2A
12
ECM-receptor interaction 36
Show member pathways
 12.11 ITGB3 ITGA2B ITGA2 GP9
13
Cell adhesion molecules (CAMs) 36
12.07 ICOSLG CD8A CD40LG CD4
14
Phagosome 36
12.07 ITGB3 ITGA2 FCGR2C FCGR2B FCGR2A
15
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
12.02 FCGR2B CD8A CD40LG CD19
16
Osteoclast differentiation 36
11.99 ITGB3 FCGR2C FCGR2B FCGR2A
17
Reelin Pathway (Cajal-Retzius cells) 63
11.92 ITGB3 ITGA2B ITGA2 CD19
18
Platelet activation 36
11.92 ITGB3 ITGA2B ITGA2 GP9 FCGR2A
19
Staphylococcus aureus infection 36
11.85 IL10 FCGR2C FCGR2B FCGR2A
20
Phagocytosis of Microbes 63
11.78 ITGB3 ITGA2B ITGA2 FCGR2A
21
Innate Lymphoid Cell Differentiation Pathways 64
11.74 IL10 CD8A CD4 CCR6
22
Integrin alphaIIb beta3 signaling 65
Show member pathways
 11.71 THPO MPL ITGB3 ITGA2B GP9
23
Dendritic Cells Developmental Lineage Pathway 64
11.69 IL10 CD8A CD4 CD19
24
IL4-mediated signaling events 1
11.62 ITGB3 IL10 CD40LG
25
ECM proteoglycans 65
11.57 ITGB3 ITGA2B ITGA2
26
Hematopoietic cell lineage 36
11.55 THPO ITGB3 ITGA2B ITGA2 GP9 CD8A
27
Signaling events mediated by PTP1B 1
11.5 ITGB3 ITGA2B FCGR2A
28
B Cell Development Pathways 64
11.5 IL10 CD40LG CD4 CD19
29
Hematopoietic Stem Cell Differentiation 1
11.48 ITGB3 ITGA2B GP9
30
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.47 ITGB3 ITGA2B ITGA2 GP9
31
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.4 ITGB3 IL10 FCGR2C FCGR2B FCGR2A
32
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.39 THPO MPL ITGB3 ITGA2B ITGA2 IL10
33
Primary immunodeficiency 36
11.25 CD8A CD40LG CD4 CD19
34
Platelet Adhesion to exposed collagen 65
10.78 ITGA2 GP9
35
G-protein signaling_Rap2B regulation pathway 22
10.76 TNFSF13B THPO PF4 ITGB3 ITGA2B ITGA2
Sources

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.06 TNFSF13B MPL ITGB3 ITGA2B ITGA2 ICOSLG
2 integral component of plasma membrane GO:0005887 9.97 ITGB3 GP9 FCGR2B CD8A CD40LG CD4
3 plasma membrane GO:0005886 9.86 TNFSF13B MPL ITGB3 ITGA2B ITGA2 ICOSLG
4 cell surface GO:0009986 9.8 MPL ITGB3 ITGA2B ITGA2 CD40LG CD4
5 integrin complex GO:0008305 9.5 ITGB3 ITGA2B ITGA2
6 external side of plasma membrane GO:0009897 9.32 ITGA2B ITGA2 ICOSLG FCGRT FCGR2B CD8A

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of T cell proliferation GO:0042102 9.67 TNFSF13B CD40LG CD4
2 T cell costimulation GO:0031295 9.65 TNFSF13B ICOSLG CD40LG
3 T cell activation GO:0042110 9.63 ICOSLG CD8A CD4
4 platelet activation GO:0030168 9.56 PF4 ITGB3 GP9 CD40LG
5 mesodermal cell differentiation GO:0048333 9.54 ITGB3 ITGA2
6 immunoglobulin mediated immune response GO:0016064 9.52 FCGR2B CD19
7 positive regulation of leukocyte migration GO:0002687 9.51 ITGA2B ITGA2
8 platelet aggregation GO:0070527 9.5 MPL ITGB3 ITGA2B
9 integrin-mediated signaling pathway GO:0007229 9.46 ITGB3 ITGA2B ITGA2 CD40LG
10 immunoglobulin secretion GO:0048305 9.43 TNFSF13B CD40LG
11 regulation of immune response GO:0050776 9.43 TNFSF13B ICOSLG FCGR2B CD8A CD40LG CD19
12 negative regulation of MHC class II biosynthetic process GO:0045347 9.4 PF4 IL10
13 thrombopoietin-mediated signaling pathway GO:0038163 9.37 THPO MPL
14 immune response GO:0006955 9.32 TNFSF13B PF4 IL10 FCGRT FCGR2C FCGR2B

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.5 ITGB3 ITGA2 CD4
2 cytokine activity GO:0005125 9.35 TNFSF13B THPO PF4 IL10 CD40LG
3 coreceptor activity GO:0015026 9.33 ITGB3 CD8A CD4
4 fibrinogen binding GO:0070051 9.26 ITGB3 ITGA2B
5 IgG binding GO:0019864 8.92 FCGRT FCGR2C FCGR2B FCGR2A
Sources

Sources for Thrombocytopenia Due to Platelet Alloimmunization

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....